Patents by Inventor Robert Finberg

Robert Finberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200172868
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating an infectious disease. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having an infectious disease.
    Type: Application
    Filed: July 19, 2017
    Publication date: June 4, 2020
    Inventors: Tom Wickham, Tiffany F. Chen, Nathan Dowden, Robert Finberg, Robert J. Deans, John Round, Avak Kahvejian, Jordi Mata-Fink, Noubar B. Afeyan
  • Patent number: 9408890
    Abstract: This disclosure provides compositions, kits, and methods useful for treating or preventing viral and bacterial infection and reducing or preventing the effects of toxins. The methods comprise administering to a subject an effective amount of a liposomal composition.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: August 9, 2016
    Assignees: The Charles Stark Draper Laboratory, Inc., The Massachusetts Institute of Technology, University of California, Santa Barbara (UCSB), University of Massachusetts Medical School
    Inventors: James Comolli, Jose Trevejo, Ram Sasisekharan, Zachary Shriver, Karthik Viswanathan, Deborah Fygenson, Robert Finberg, Jennifer Wang
  • Publication number: 20150158956
    Abstract: This disclosure provides compositions, kits, and methods useful for treating or preventing viral infection. The methods comprise administering to a subject an effective amount of a sulfated polysaccharide composition.
    Type: Application
    Filed: October 20, 2014
    Publication date: June 11, 2015
    Inventors: James Comolli, Robert Finberg, Deborah K. Fygenson, Zachary Shriver, Ram Sasisekharan, Jennifer Wang, Karthik Viswanathan
  • Publication number: 20140255470
    Abstract: This disclosure provides compositions, kits, and methods useful for treating or preventing viral and bacterial infection and reducing or preventing the effects of toxins. The methods comprise administering to a subject an effective amount of a liposomal composition.
    Type: Application
    Filed: January 22, 2014
    Publication date: September 11, 2014
    Applicant: The Charles Stark Draper Laboratory, Inc.
    Inventors: James Comolli, Jose Trevejo, Ram Sasissekharan, Zachary Shriver, Karthik Viswanathan, Deborah Fygenson, Robert Finberg, Jennifer Wang
  • Patent number: 7223411
    Abstract: A herpesvirus vaccine comprising a mutated herpesvirus suspended in a pharmaceutically acceptable carrier. The mutated herpesvirus is capable of infecting cells of the mammal to be vaccinated, but incapable of completing a replicative cycle, and it is capable of eliciting a protective immune response in that mammal. The mutated herpesvirus is also capable of treating immunomodulatory or immunoregulatory diseases. The mutation occurs in at least one gene encoding a protein essential for replication of the virus, so that the mutation renders the virus replication defective.
    Type: Grant
    Filed: July 21, 1994
    Date of Patent: May 29, 2007
    Assignees: Dana-Farber Cancer Institute, President & Fellows of Harvard College
    Inventors: David Knipe, Robert Finberg, George Siber
  • Publication number: 20060018912
    Abstract: The present invention provides a snare molecules comprising an attachment moiety (which facilitates attachment of a receptor to a cell) and a receptor for a toxic pathogenic or infectious agent, e.g., a virus.
    Type: Application
    Filed: May 27, 2005
    Publication date: January 26, 2006
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: Robert Finberg, Damon Asher
  • Publication number: 20050164172
    Abstract: Toll-like receptor 2 (TLR2) has been found to mediate certain effects of HSV infection, particularly in neonates. Compounds that decrease TLR2 expression or activity are useful for ameliorating such deleterious effects.
    Type: Application
    Filed: January 21, 2005
    Publication date: July 28, 2005
    Inventors: Evelyn Kurt-Jones, Robert Finberg
  • Publication number: 20050074823
    Abstract: It has been found that Toll-like receptor 1 and Toll-like receptor 2 (TLR2) physically interact. Antibodies that specifically bind to TLR2 and selectively inhibit induction of cytokines are also described. The invention relates to specific antibodies that selectively bind to TLR2, and to methods of identifying compounds that selectively interfere with signaling through TLR1/TLR2 complexes.
    Type: Application
    Filed: August 20, 2004
    Publication date: April 7, 2005
    Inventors: Evelyn Kurt-Jones, Robert Finberg
  • Publication number: 20050028230
    Abstract: The present invention is directed, at least in part, to mice which express exogenous complement receptor type 1 (CR1) on red blood cells. The invention also pertains to genetic constructs encoding heterologous CR1 for expression on red blood cells. Methods of using the transgenic animals of the invention to identify and/or evaluate compositions that can reduce the concentration of an agent, e.g., a biologic agent, in the serum, circulation and/or tissues of a subject are also provided.
    Type: Application
    Filed: May 10, 2004
    Publication date: February 3, 2005
    Inventor: Robert Finberg
  • Publication number: 20020086035
    Abstract: A herpesvirus vaccine comprising a mutated herpesvirus suspended in a pharmaceutically acceptable carrier. The mutated herpesvirus is capable of infecting cells of the mammal to be vaccinated, but incapable of completing a replicative cycle, and it is capable of eliciting a protective immune response in that mammal. The mutated herpesvirus is also capable of treating immunomodulatory or immunoregulatory diseases. The mutation occurs in at least one gene encoding a protein essential for replication of the virus, so that the mutation renders the virus replication defective.
    Type: Application
    Filed: March 4, 1998
    Publication date: July 4, 2002
    Inventors: DAVID M. KNIPE, ROBERT FINBERG, GEORGE SIBER
  • Publication number: 20020009462
    Abstract: A herpesvirus vaccine comprising a mutated herpesvirus suspended in a pharmaceutically acceptable carrier. The mutated herpesvirus is capable of infecting cells of the mammal to be vaccinated, but incapable of completing a replicative cycle, and it is capable of eliciting a protective immune response in that mammal. The mutated herpesvirus is also capable of treating immunomodulatory or immunoregulatory diseases. The mutation occurs in at least one gene encoding a protein essential for replication of the virus, so that the mutation renders the virus replication defective.
    Type: Application
    Filed: July 31, 1997
    Publication date: January 24, 2002
    Inventors: DAVID M. KNIPE, ROBERT FINBERG, GEORGE SIBER
  • Patent number: 6195426
    Abstract: A communication system that provides information to customers holding in a queue. Upon arrival to the queue, the queue identifies the customer and further identifies information that is related to the customer's motivation for entering the queue from the customer's identity. The queue selects individual messages from the relevant information for presentation to the customer. Certain messages may be prioritized over others based on the queue experience with other customers or based on external events that raise the likelihood that the message is relevant. The communication system may operate in a telecommunication network or a computer network.
    Type: Grant
    Filed: December 11, 1997
    Date of Patent: February 27, 2001
    Assignee: AT&T Corp.
    Inventors: Raymond L. Bolduc, Robert Finberg, Robert Edward Markowitz, Kenneth H. Rosen, Steven Charles Salimando
  • Patent number: 5282243
    Abstract: In order to enable an "800" telephone number business subscriber to identify customers, whose incoming telephone calls were blocked, the Automatic Number Identification (ANI) of these calling customer is automatically recorded within the telecommunications network for later access by the business subscriber.
    Type: Grant
    Filed: November 6, 1992
    Date of Patent: January 25, 1994
    Assignee: AT&T Bell Laboratories
    Inventors: Hassan Dabbaghi, Robert Finberg, Albert Friedes, Lisa C. Giulianelli, Angela R. Gore, Nadine Grasty, Susan E. Grove, Carlos Perea, Paramdeep S. Sahni, Susan M. Zoccolillo